The monoclonal antibody natalizumab (NAT) inhibits the migration of lymphocytes throughout the blood–brain barrier by blocking very late antigen (VLA)-4 interactions, thereby reducing inflammatory central nervous system (CNS) activity in patients with multiple sclerosis (MS). We evaluated the effects of different NAT treatment regimens.
Tjalf Ziemssen合作论文数CeTI;Universitätsklinikum Carl Gustav Carus Dresden;Dresden International University33
T. Sehr合作论文数13
Undine Hainke合作论文数10M. Marggraf合作论文数10Thorsten Schultheiss合作论文数9J. Eisele合作论文数8L. Hayardeny合作论文数3Undine Proschmann合作论文数3R. Kern合作论文数3M. Kaufmann合作论文数3
Haase Rocco合作论文数Neurological Outpatient Center3R. Kempcke合作论文数2
Heinz Reichmann合作论文数Institute and Outpatient Clinics of Neurology, Dresden University of Technology;Department of Neurology, Dresden University of Technology2
Lis Neubeck合作论文数Concord Hospital, University of Sydney and ANZAC Research Institute2J. C. Eisele合作论文数1W. Brueck合作论文数1
Michael Bachmann合作论文数1Robert Bucki合作论文数1S. Matko合作论文数1U. Engelmann合作论文数1
Simone Kern合作论文数1
Chan Andrew K合作论文数From the Department of Neurological Surgery, Columbia University Medical Center;Weill Cornell Medical College, Cornell University;Department of Neurology, Columbia University Medical Center;Columbia University Medical Center, Columbia University Medical Center1
Marcus Odendahl合作论文数1Shammas Layal合作论文数1H Tumani合作论文数1Hey S合作论文数1Silke Prieur合作论文数1
Kerstin Hellwig合作论文数St. Josef Hospital, Ruhr University Bochum1Marc Schmitz合作论文数1Małgorzata Żendzian-Piotrowska合作论文数1
Torsten Tonn合作论文数Institut für Transfusionsmedizin Dresden;DRK-Blutspendienst Nord-Ost gGmbH;Transfusion Medicine at the Carl Gustav Carus Medical Faculty, Technische Universität Dresden1H Hanso合作论文数1Marc Cartellieri合作论文数1Manja Reimann合作论文数1
